UPDATE: Wedbush Lowers Illumina's PT

Loading...
Loading...
According to a research report published this morning, Wedbush has decreased Illumina's
ILMN
PT from $65 to $52. In the report, Wedbush commented, "With Roche out of the picture, we have reassessed our valuation framework. We are lowering our price target from $65 to $52, which assumes a 2012E EV/sales multiple of 5.5x versus our prior 7.5x multiple, which was based on the price Roche paid for Ventana in 2008. Additionally our $52 price target assumes a 2012E FCF yield of 4.6%, in line with the current diagnostics peer group median." Wedbush maintains its Outperform rating on Illumina, which closed yesterday at $43.90.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsWedbush
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...